Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Central Nervous System
  4. Back
  5. Myasthenia
  6. Pyridostigmine for Myasthenia Gravis Q&A (1061)

Pyridostigmine for Myasthenia Gravis Q&A (1061)

Warning

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 19/03/2026

Next review date: 31/12/2028

Author(s): Samuel Hayes.

Version: 2

Approved By: Medicines Utilisation Subcommittee of ADTC

Document Id: 1061

References
  1. Mylan Products Summary of Product Characteristics. Mestinon 60mg tablets. Last revised 11/04/2024. Accessed via www.medicines.org.uk September 2025
  2. Joint Formulary British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed via www.medicinescomplete.com September 2025
  3. Wrexham Maelor Hospital Pharmacy The NEWT Guidelines. Accessed via www.newtguidelines.com September 2025
  4. White R, Bradnam Handbook of Drug administration via Enteral Feeding Tubes. Pharmaceutical Press. Accessed via www.medicinescomplete.com September 2025
  5. Specialist Pharmacy Switching between neostigmine and pyridostigmine in myasthenia gravis. Published 25th October 2022. Accessed via www.sps.nhs.uk
  6. Jacob S, Farrugia ME, Hewamadduma C, et Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). Pract Neurol 2025;25:422–437.
  7. Pascuzzi RM, Bodkin Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment. Neuropsychiatr Dis Treat. 2022 Dec 22;18:3001-3022.